Ligand id: 7603

Name: levomepromazine

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: levomepromazine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 41.01
Molecular weight 328.16
XLogP 4.21
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used extensively in palliative care to treat intractable nausea or vomiting and to alleviate severe end-stage delirium and/or agitation. May also be used to treat psychosis (schizophrenia, and manic phases of bipolar disorder) and nausea and insomnia at low dose. There is no information regarding approval of ths drug on either the US FDA or EMA websites. Individual national approval agencies may have granted marketing authorisation for this drug (eg UK in 2009).
Mechanism Of Action and Pharmacodynamic Effects
The major clinical benefits of levomepromazine arise from its antagonism of D2-like dopamine receptor in the CNS and from its antihistamine activity. However, in addition, levomepromazine interacts with a wide spectrum of other receptors including adrenergic, muscarinic acetylcholine and serotonin receptors.
External links